SCHEMBL1574949

SCHEMBL1574949

CCN(CC)C1CN(C(=O)Nc2ccc(Cl)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.52
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
TAS1R2 Q8TE23 1/20 0.50
LMNA P02545 4/20 0.48
MAPT P10636 4/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
TP53 P04637 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
KMT2A Q03164 3/20 0.46
GAA P10253 2/20 0.46
CCR1 P32246 1/20 0.46
KDM4E B2RXH2 2/20 0.45
CA12 O43570 1/20 0.45
CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575353 0.89 ALOX5 (0.50) ALOX5TAS1R3TAS1R1TAS1R2LMNA
SCHEMBL1574617 0.87 NPC1 (0.54) TAS1R3TAS1R1TAS1R2LMNAMAPT
SCHEMBL1574441 0.86 NPC1 (0.54) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1575780 0.86 NPSR1 (0.54) MAPTSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL1574769 0.86 KMT2A (0.52) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1574517 0.86 HPGD (0.55) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1574609 0.85 ALOX5 (0.49) ALOX5TAS1R3TAS1R1TAS1R2LMNA
SCHEMBL1574671 0.85 ALOX5 (0.54) ALOX5TAS1R3TAS1R1TAS1R2LMNA
SCHEMBL1574991 0.84 ALDH1A1 (0.58) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL1573945 0.84 TAS1R3 (0.54) ALOX5TAS1R3TAS1R1TAS1R2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB ALOX5 16/4885TAS1R3 4140/4885TAS1R1 4237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.